GSK Announces Depemokimab Late-Breaking Data Presented At ERS Show A 54% Reduction In Severe Asthma Exacerbations; SWIFT-1 And SWIFT-2 Phase III Data Show Depemokimab Delivered Significant And Clinically Meaningful Reduction In Exacerbations Over 52...

GSk宣佈Depemokimab在ERS展示的後期數據，顯示嚴重哮喘惡化減少54％；SWIFt-1和SWIFt-2階段III數據顯示Depemokimab在52周內顯著且具有臨床意義的減少惡化。

Benzinga · 09/09 21:38

GSK Announces Depemokimab Late-Breaking Data Presented At ERS Show A 54% Reduction In Severe Asthma Exacerbations; SWIFT-1 And SWIFT-2 Phase III Data Show Depemokimab Delivered Significant And Clinically Meaningful Reduction In Exacerbations Over 52 Weeks Versus Placebo Plus Standard Of Care, In Duplicate Studies

葛蘭素史克宣佈在ERS上公佈的Depemokimab最新數據顯示，嚴重哮喘發作減少了54％；在重複的研究中，Swift-1和Swift-2 III期數據顯示，與安慰劑加標準護理相比，德培莫基單抗在52周內顯著減少了具有臨床意義的惡化

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。